SYN608, is a new molecule that is being studied for treating advanced solid tumors, including prostate cancer, in patients with specific genetic weaknesses known as homologous recombination repair (HRR) deficiencies.
The drug targets an enzyme called PARG, which helps cancer cells repair DNA damage. By blocking PARG, SYN608 causes DNA damage to accumulate, potentially killing cancer cells, particularly in HRR-deficient tumors with mutations like BRCA and ATM, common in some prostate, breast, and ovarian cancers.

Lab tests showed the drug works well alone and in cancers resistant to similar treatments, with a good safety profile and low risk of heart-related side effects.

Source.

Trial.